financetom
Business
financetom
/
Business
/
GlobalFoundries finance chief John Hollister departs, Sam Franklin named interim CFO
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
GlobalFoundries finance chief John Hollister departs, Sam Franklin named interim CFO
Oct 27, 2025 3:45 PM

(Reuters) -GlobalFoundries' ( GFS ) John Hollister has stepped down from the CFO position and will be succeeded by Sam Franklin on an interim basis, the contract chipmaker said on Monday.

The management reshuffle comes at a time when the company has pledged to invest $16 billion partly towards building more manufacturing facilities on American soil amid U.S. President Donald Trump's push to onshore supply chains.

The company, unlike leader TSMC, does not largely produce cutting-edge artificial intelligence chips and is spending heavily on upgrading its manufacturing processes to produce more advanced chips for markets such as automotive and smartphones.

While Taiwan's TSMC manufactures the most advanced processors designed by the likes of Nvidia, AMD and Qualcomm ( QCOM ), GlobalFoundries ( GFS ) produces the chips used alongside them that form an essential part of electronic systems.

Hollister, who joined the company as CFO early last year, is leaving due to "personal reasons", GlobalFoundries ( GFS ) said, without providing further details.

Franklin, who is currently vice president of business finance, operations and investor relations, joined Global Foundries in 2022.

He has previously held banking and finance positions across firms including Mubadala, a unit of Abu Dhabi's sovereign wealth fund that is also GlobalFoundries' ( GFS ) largest shareholder, according to LSEG data.

"While the company determines a permanent successor, we are confident in Sam's ability," CEO Tim Breen said in a statement.

"GF (GlobalFoundries ( GFS )) remains focused on our strategic priorities."

GlobalFoundries' ( GFS ) adjusted gross margin has struggled to break out of the 20-30% range for a large part of the last four years, with analysts citing pricing problems and increased competitive pressure.

The company is expected to report a drop of about 4% in quarterly revenue to $1.68 billion on November 12, according to data compiled by LSEG. Its profit is expected to fall 8% to $165.4 million.

(Reporting by Arsheeya Bajwa; Editing by Anil D'Silva)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Oracle Insider Sold Shares Worth $5,750,935, According to a Recent SEC Filing
Oracle Insider Sold Shares Worth $5,750,935, According to a Recent SEC Filing
Mar 20, 2024
08:44 AM EDT, 03/20/2024 (MT Newswires) -- Jeffrey Berg, Director, on March 18, 2024, sold 45,000 shares in Oracle (ORCL) for $5,750,935. Following the Form 4 filing with the SEC, Berg has control over a total of 212,409 shares of the company, with 212,409 shares controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1341439/000112760224010618/xslF345X03/form4.xml Price: 129.5, Change: +0.31, Percent Change: +0.24 ...
Boeing deliveries on track as India's Akasa goes international, CEO says
Boeing deliveries on track as India's Akasa goes international, CEO says
Mar 20, 2024
By Aditya Kalra and Aditi Shah NEW DELHI (Reuters) - India's Akasa Air is confident that deliveries of its ordered Boeing 737 MAX jets will be on time, its CEO said, despite concerns over the U.S. planemaker's production schedule for 737s amid intense scrutiny after a mid-air incident this year. India's newest airline in January announced an order for 150...
--Chardan Ups PT on Coya Therapeutics to $14 From $11 on Advancements of COYA 302 Targeting Multiple Neurodegenerative Diseases, Keeps Buy Rating
--Chardan Ups PT on Coya Therapeutics to $14 From $11 on Advancements of COYA 302 Targeting Multiple Neurodegenerative Diseases, Keeps Buy Rating
Mar 20, 2024
08:44 AM EDT, 03/20/2024 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us) Price: 10.21, Change: +0.14, Percent Change: +1.39 ...
Kyowa Kirin's gene therapy most expensive US drug with $4.3 mln price tag
Kyowa Kirin's gene therapy most expensive US drug with $4.3 mln price tag
Mar 20, 2024
March 20 (Reuters) - Orchard Therapeutics, a unit of Japan's Kyowa Kirin ( KYKOF ), priced its newly approved gene therapy for a rare, life-threatening genetic disease on Wednesday at $4.25 million, making it the most expensive drug in the United States. The therapy was approved on Monday, in a first for children with a rare disorder called metachromatic leukodystrophy...
Copyright 2023-2026 - www.financetom.com All Rights Reserved